Patents Assigned to Trustees of the University of Pennsylvania
  • Publication number: 20240229000
    Abstract: The present disclosure provides compositions and methods for site-specific labeling of antibodies by proximity-based sortase-mediated ligation. The ligation method utilizes a non-canonical isopeptide ligation reaction catalyzed by newly identified variants of S. aureus sortase A. An antibody binding domain (e.g., protein A or protein G) is fused to the variants of SrtA to bring the enzyme into close proximity of an antibody, thereby significantly increases the efficiency of isopeptide bond formation.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 11, 2024
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, AlphaThera LLC
    Inventors: Andrew TSOURKAS, Wendy YU, Wendy Yu, Per-Åke Nygren
  • Publication number: 20240226179
    Abstract: This disclosure provides a culture media that facilitates survival and/or engraftment of transplanted cells. In one embodiment, this culture media comprises collagen I, albumin, L-glutamine and NaHCO3. In one embodiment, this culture media promotes enhanced survival and engraftment of ?-cells of human pancreatic islets transplanted under the skin. The protective effect of this culture media is mediated, at least partly, by upregulating anti-apoptotic signaling pathways.
    Type: Application
    Filed: March 1, 2021
    Publication date: July 11, 2024
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Ali NAJI, Ming YU
  • Publication number: 20240226154
    Abstract: The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL-18), compositions comprising the T cells, and methods of generating and/or using the T cells to treat diseases associated with the expression of CD19.
    Type: Application
    Filed: October 18, 2023
    Publication date: July 11, 2024
    Applicants: Kite Pharma, Inc., The Trustees of the University of Pennsylvania
    Inventors: Neil C. Sheppard, Yanping Luo, David Barrett, Regina Young
  • Patent number: 12029745
    Abstract: The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: July 9, 2024
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Melpo Christofidou-Solomidou, Angela Haczku
  • Patent number: 12029760
    Abstract: The present invention includes compositions and methods for modifying primary T cells. In one aspect, the invention comprises administering to a cell a stem-loop Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (st-crRNA) and a Cpf1 enzyme.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: July 9, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Jiangtao Ren
  • Patent number: 12029907
    Abstract: Methods and apparatus for improving cognitive function within a human. The invention utilizes a neurostimulation device, such as a signal generator, to affect tissue elements at a lateral temporal lobe of the human brain. The implanted device delivers treatment therapy to thereby improve cognitive function by the human. A sensor may be used to detect various characteristics of cognition. A microprocessor algorithm may then analyze the output from the sensor to regulate delivery of the stimulation therapy.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: July 9, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Michael Kahana, Daniel Sutton Rizzuto
  • Publication number: 20240218394
    Abstract: Compositions and methods are provided for treating ocular neuropathy in a subject. In one aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding NRF2. In another aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding SIRT1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.
    Type: Application
    Filed: November 8, 2023
    Publication date: July 4, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Jean Bennett, Junwei Sun, Kenneth Shindler, Devin McDougald, Ahmara Gibbons Ross
  • Publication number: 20240218018
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus and/or C-terminus contains an added component that improves (1) the peptide's solubility at physiological pH; (2) the peptide's plasma half-life; (3) the peptide's intraocular retention; and/or (4) the peptide's binding affinity to C3 or its fragments as compared to an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Application
    Filed: January 29, 2024
    Publication date: July 4, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventor: John D. Lambris
  • Patent number: 12023376
    Abstract: Immunogenic compositions and methods of their use in eliciting immune responses to coronaviruses, such as SARS-CoV-2 are provided.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: July 2, 2024
    Assignees: Triad National Security, LLC, Oxford University Innovation Limited, The Trustees of the University of Pennsylvania, Beth Israel Deconess Medical Center, Inc.
    Inventors: Bette T. M. Korber, James Theiler, Dan Barouch, Drew Weissman, Tomas Hanke
  • Patent number: 12023386
    Abstract: The invention provides a polynucleotide sequence (e.g., a gene, e.g., DNA or RNA) encoding UGT1A1 (e.g., expressing human UGT1A1). The invention further provides a vector, such as an adeno-associated virus (AAV) vector (e.g., AAV8) having a vector genome including inverted terminal repeat sequences and a UGT1A1 coding sequence operably linked to one or more expression control sequences (e.g., expression control sequences including a liver-specific promoter). Also provided are compositions containing these AAV vectors and methods of treating Crigler-Nijjar syndrome type I, Crigler-Nijjar syndrome type II, and Gilbert syndrome.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: July 2, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Anna P. Tretiakova, Jenny Agnes Sidrane, James M. Wilson
  • Publication number: 20240207452
    Abstract: Provided herein are compositions including brain-capillary binding and/or blood-brain barrier crossing (BBB) tissue-targeting peptides linked thereto or inserted in a targeting protein of a recombinant vector having at least one exogenous peptide comprising an amino acid sequence of Y-G/A/R/K-Y/H-GNPA-T/R/H-RYFD-V/K. Compositions providing such conjugates, targeting peptides, or recombinant vectors having a mutant capsid or envelope protein are provided as are uses thereof.
    Type: Application
    Filed: April 22, 2022
    Publication date: June 27, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Joshua Joyner SIMS, James M. WILSON, Yuan YUAN
  • Publication number: 20240209316
    Abstract: The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like receptor agonists that induce clinically effective immune responses, preferably when used earlier in the disease process. The DCs of the present invention produce desirable levels of cytokines and chemokines, and further have the capacity to induce apoptosis of tumor cells. The cells can be cryopreserved and thawed for later use, thereby reducing the need for repeated pheresis and elutriation processes during vaccine production. These methods can also be utilized to directly target molecules involved in carcinogenetic signaling pathways and cancer stem cells.
    Type: Application
    Filed: August 4, 2023
    Publication date: June 27, 2024
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Brian J. CZERNIECKI, Ursula KOLDOVSKY, Shuwen XU, Gary K. KOSKI
  • Patent number: 12019736
    Abstract: Methods, systems, and computer readable media for using metadata tag compression. A method occurs at a metadata processing system for enforcing security policies in a processor architecture. The method comprises: receiving, at the metadata processing system, a short tag associated with a word in memory; translating the short tag, using a tag map, into a long tag, wherein the short tag indicates a location of the long tag relative to an offset in the tag map and wherein the long tag indicates a memory location containing metadata associated with the word or an instruction; obtaining the metadata from the memory location; and determining, using the metadata, whether the word or the instruction violates a security policy.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: June 25, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Andre Maurice DeHon, Nicholas Edward Roessler
  • Patent number: 12020861
    Abstract: The subject matter described herein relates to laminated magnetic cores, methods of fabricating laminated magnetic cores, and electric devices using laminated magnetic cores. In some examples, a method for fabricating a laminated magnetic core includes depositing a first magnetic layer and depositing an interlamination layer of over the first magnetic layer. The interlamination layer comprises a partially conducting material having a conductivity greater than or equal to 10?4 S/cm and less than or equal to 105 S/cm. The method includes depositing a second magnetic layer over the interlamination layer. The method can include sequentially depositing additional interlamination layers and additional magnetic layers in an alternating fashion to produce the laminated magnetic core.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: June 25, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark George Allen, Min Soo Kim
  • Patent number: 12018279
    Abstract: This present disclosure relates to a bioengineering approach based on microphysiological culture to mimic tissue-tissue interface. Accordingly, the present disclosure provides methods, compositions and kits related to the approach.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: June 25, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Sunghee Estelle Park, Wenli Yang, Dwight E. Stambolian, Dongeun Huh
  • Publication number: 20240197916
    Abstract: A dual vector system for treating a genetic disorder is provided. The system includes (a) a gene editing vector comprising an expression cassette comprising a nucleic acid sequence encoding a nuclease and regulatory sequences that direct expression of the nuclease in a target cell comprising a PCSK9 gene; and (b) a donor vector comprising a nucleic acid sequence encoding an exogenous product for expression from the PCSK9 locus, wherein the inserted nucleic acid sequence does not encode PCSK9, wherein the system further comprises sequences that direct the nuclease to specifically targets the native PCSK9 gene locus; and wherein the native PCSK9 in the target cell is optionally ablated or reduced post-dosing with the dual vector system.
    Type: Application
    Filed: April 27, 2022
    Publication date: June 20, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson, Anna Tretiakova
  • Publication number: 20240191258
    Abstract: Compositions useful for treatment of Spinal and Bulbar Muscular Atrophy (SBMA) comprising administration of a recombinant adeno-associated virus (rAAV) vector having an AAV capsid and a vector genome comprising a sequence encoding at least one hairpin forming miRNA that comprises a targeting sequence which binds a target site on the mRNA of human androgen receptor, wherein the miRNA inhibits expression of human androgen receptor, is provided. Also provided are compositions containing a rAAV vector and methods of treating SBMA in patient comprising administration of a rAAV vector.
    Type: Application
    Filed: April 12, 2022
    Publication date: June 13, 2024
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Christian Hinderer, Eileen Workman
  • Patent number: 12004882
    Abstract: An adaptive real-time radial k-space sampling trajectory (ARKS) can respond to a physiologic feedback signal to reduce motion effects and ensure sampling uniformity. In this adaptive k-space sampling strategy, the most recent signals from an ECG waveform can be continuously matched to the previous signal history, new radial k-space locations were determined, and these MR signals combined using multi-shot or single-shot radial acquisition schemes. The disclosed methods allow for improved MRI imaging.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 11, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Walter R. T. Witschey, Francisco Contijoch, Mark A. Elliott, Eugene E. Gualtieri
  • Patent number: 11999794
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: June 4, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Patent number: 11998331
    Abstract: The present invention relates to the discovery that the expression levels of some microRNAs (miRNAs) can use a diagnostic signature to predict transplant outcomes in a transplant recipient. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a transplant subject for acute rejection such as acute cellular rejection (ACR), methods of predicting a subject's risk of having or developing ACR and methods of assessing in a subject the likelihood of a successful or failure minimization of immunosuppression therapy (IST) dosage from standard ranges.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: June 4, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Abraham Shaked, Bao-Li Chang, Brendan Keating, Toumy Guettouche